NASDAQ:ATRA - Atara Biotherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.25
  • Forecasted Upside: 87.47 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$18.27
▼ -0.75 (-3.94%)
1 month | 3 months | 12 months
Get New Atara Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATRA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$34.25
▲ +87.47% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. The average price target is $34.25, with a high forecast of $78.00 and a low forecast of $14.00. The average price target represents a 87.47% upside from the last price of $18.27.
Buy
The current consensus among 10 investment analysts is to buy stock in Atara Biotherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/9/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$20.00 ➝ $27.00High
i
12/9/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngradeBuy ➝ Neutral$20.00 ➝ $27.00High
i
12/8/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $31.00Medium
i
Rating by Robert Burns at HC Wainwright
12/7/2020Stifel NicolausBoost Price TargetBuy$28.00 ➝ $33.00Medium
i
11/23/2020MizuhoBoost Price TargetBuy$38.00 ➝ $41.00Low
i
11/13/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$14.00 ➝ $20.00Low
i
11/13/2020Smith Barney CitigroupBoost Price Target$14.00 ➝ $20.00Low
i
11/10/2020HC WainwrightBoost Price TargetBuy$26.00 ➝ $28.00High
i
Rating by Robert Burns at HC Wainwright
9/24/2020William BlairReiterated RatingBuyHigh
i
9/14/2020Canaccord GenuityBoost Price TargetBuy$70.00 ➝ $78.00Medium
i
8/6/2020Stifel NicolausLower Price TargetBuy$30.00 ➝ $28.00Low
i
8/6/2020HC WainwrightBoost Price TargetBuy$25.00 ➝ $26.00High
i
Rating by R. Burns at HC Wainwright
7/17/2020Canaccord GenuityReiterated RatingBuy$70.00Medium
i
6/30/2020Evercore ISIInitiated CoverageOutperformMedium
i
6/15/2020HC WainwrightInitiated CoverageBuy$25.00High
i
Rating by R. Burns at HC Wainwright
5/26/2020MizuhoInitiated CoverageBuy$38.00High
i
Rating by Salim Syed at Mizuho
5/19/2020MizuhoInitiated CoverageBuy$38.00High
i
Rating by Salim Syed at Mizuho
5/12/2020JPMorgan Chase & Co.Boost Price TargetNeutral$22.00 ➝ $23.00High
i
4/23/2020CitigroupUpgradeNeutral ➝ Buy$14.00High
i
2/18/2020Canaccord GenuityReiterated RatingBuyHigh
i
12/10/2019CowenReiterated RatingBuyMedium
i
Rating by Phil Nadeau at Cowen Inc
11/8/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$43.00 ➝ $22.00Low
i
10/25/2019Stifel NicolausReiterated RatingBuyLow
i
Rating by Benjamin Burnett at Stifel Nicolaus
9/27/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$14.00 ➝ $9.00Medium
i
9/18/2019MizuhoSet Price TargetBuy$43.00Low
i
Rating by Salim Syed at Mizuho
9/16/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$32.00 ➝ $15.00Medium
i
9/13/2019Stifel NicolausSet Price TargetBuy$36.00Low
i
Rating by Benjamin Burnett at Stifel Nicolaus
9/13/2019CowenReiterated RatingBuyHigh
i
Rating by Phil Nadeau at Cowen Inc
9/13/2019Roth CapitalInitiated CoverageBuy$30.00High
i
Rating by Anthony Butler at Roth Capital
9/11/2019MizuhoSet Price TargetBuy$43.00Medium
i
8/12/2019CitigroupSet Price TargetHold$14.00High
i
Rating by Yigal Nochomovitz at Citigroup Inc.
7/16/2019CowenReiterated RatingBuyHigh
i
7/1/2019Canaccord GenuityReiterated RatingBuy$70.00Medium
i
6/3/2019CitigroupUpgradeSell ➝ Neutral$23.00 ➝ $24.00High
i
5/30/2019Roth CapitalInitiated CoverageBuy$30.00Medium
i
Rating by T. Butler at Roth Capital
5/29/2019WedbushReiterated RatingOutperformHigh
i
5/22/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$41.00Low
i
5/16/2019William BlairReiterated RatingBuyLow
i
Rating by Matt Phipps at William Blair
5/9/2019MizuhoReiterated RatingBuy$62.00High
i
4/21/2019MizuhoReiterated RatingBuy$62.00Low
i
4/1/2019William BlairReiterated RatingOutperformLow
i
2/26/2019CowenReiterated RatingBuyHigh
i
2/26/2019MizuhoReiterated RatingBuy$62.00High
i
1/22/2019MizuhoInitiated CoverageBuy ➝ Buy$62.00Low
i
11/30/2018CowenReiterated RatingBuyHigh
i
8/3/2018Jefferies Financial GroupReiterated RatingBuy$45.00Low
i
6/11/2018CitigroupLower Price TargetSell ➝ Sell$25.00 ➝ $23.00Medium
i
5/8/2018Canaccord GenuityReiterated RatingBuy$70.00Medium
i
4/10/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$56.00High
i
4/6/2018William BlairReiterated RatingBuyMedium
i
3/20/2018William BlairReiterated RatingOutperformHigh
i
3/15/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
i
3/13/2018Canaccord GenuityReiterated RatingBuy$70.00Low
i
3/5/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$30.00 ➝ $46.00High
i
2/28/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
i
2/15/2018CitigroupDowngradeNeutral ➝ SellHigh
i
1/26/2018CowenInitiated CoverageOutperformHigh
i
1/19/2018Canaccord GenuityReiterated RatingBuy ➝ Positive$47.00 ➝ $70.00Low
i
Rating by John Newman at Canaccord Genuity
1/3/2018CitigroupUpgradeSell ➝ Neutral$18.00High
i
12/29/2017Canaccord GenuityReiterated RatingBuyLow
i
Rating by John Newman at Canaccord Genuity
11/9/2017Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$20.00N/A
i
10/5/2017Jefferies Financial GroupReiterated RatingBuy$30.00N/A
i
9/11/2017Canaccord GenuityReiterated RatingBuy$47.00High
i
Rating by John Newman at Canaccord Genuity
8/31/2017Jefferies Financial GroupReiterated RatingBuy$30.00High
i
8/7/2017Canaccord GenuitySet Price TargetBuy$47.00High
i
Rating by John Newman at Canaccord Genuity
6/26/2017William BlairReiterated RatingOutperformMedium
i
Rating by M. Phipps at William Blair
6/22/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$30.00Medium
i
4/21/2017Canaccord GenuityReiterated RatingBuy$47.00Medium
i
Rating by John Newman at Canaccord Genuity
3/16/2017CitigroupSet Price TargetSell$10.00High
i
Rating by Yigal Nochomovitz at Citigroup Inc.
3/11/2017Canaccord GenuitySet Price TargetBuy$47.00High
i
Rating by John Newman at Canaccord Genuity
1/18/2017Canaccord GenuitySet Price TargetBuy$47.00N/A
i
Rating by John Newman at Canaccord Genuity
12/12/2016Canaccord GenuitySet Price TargetBuy$47.00N/A
i
Rating by John Newman at Canaccord Genuity
12/12/2016Jefferies Financial GroupSet Price TargetBuy$23.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
12/6/2016Canaccord GenuitySet Price TargetBuy$47.00N/A
i
Rating by John Newman at Canaccord Genuity
11/6/2016Canaccord GenuitySet Price TargetBuy$47.00N/A
i
Rating by John Newman at Canaccord Genuity
10/24/2016Jefferies Financial GroupInitiated CoverageBuy$25.00 ➝ $23.00N/A
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
9/15/2016The Goldman Sachs GroupDowngradeNeutral ➝ Sell$23.00 ➝ $16.00N/A
i
8/19/2016CitigroupBoost Price TargetSell$8.00 ➝ $10.00N/A
i
8/9/2016Jefferies Financial GroupReiterated RatingBuy$25.00N/A
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
7/10/2016Jefferies Financial GroupReiterated RatingBuy$25.00N/A
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
7/9/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Michael King at JMP Securities
6/7/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
6/7/2016Jefferies Financial GroupReiterated RatingBuy$22.00 ➝ $25.00N/A
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
5/9/2016Jefferies Financial GroupReiterated RatingBuy$26.00 ➝ $22.00N/A
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
5/6/2016Canaccord GenuityReiterated RatingBuy$47.00N/A
i
Rating by John Newman at Canaccord Genuity
4/9/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$40.00 ➝ $34.00N/A
i
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$40.00 ➝ $34.00N/A
i
3/6/2016Canaccord GenuityReiterated RatingBuy$47.00N/A
i
Rating by John Newman at Canaccord Genuity
2/22/2016Canaccord GenuityInitiated CoverageBuyN/A
i
Rating by John Newman at Canaccord Genuity
2/22/2016The Goldman Sachs GroupLower Price Target$30.00 ➝ $24.00N/A
i
Rating by Terence Flynn at The Goldman Sachs Group, Inc.
2/19/2016CitigroupLower Price Target$16.00 ➝ $13.00N/A
i
Rating by Yigal Nochomovitz at Citigroup Inc.
2/17/2016Jefferies Financial GroupReiterated RatingBuy$26.00N/A
i
2/16/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
(Data available from 1/20/2016 forward)
Atara Biotherapeutics logo
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was founded in 2012 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $18.27
$18.22
$19.26

50 Day Range

MA: $21.51
$18.61
$26.23

52 Week Range

Now: $18.27
$4.52
$28.20

Volume

613,103 shs

Average Volume

929,666 shs

Market Capitalization

$1.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Atara Biotherapeutics?

The following equities research analysts have issued reports on Atara Biotherapeutics in the last twelve months: Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Mizuho, Smith Barney Citigroup, Stifel Nicolaus, William Blair, and Zacks Investment Research.

What is the current price target for Atara Biotherapeutics?

8 Wall Street analysts have set twelve-month price targets for Atara Biotherapeutics in the last year. Their average twelve-month price target is $34.25, suggesting a possible upside of 80.1%. Canaccord Genuity has the highest price target set, predicting ATRA will reach $78.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $14.00 for Atara Biotherapeutics in the next year.

What is the current consensus analyst rating for Atara Biotherapeutics?

Atara Biotherapeutics currently has 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATRA will outperform the market and that investors should add to their positions of Atara Biotherapeutics.

What other companies compete with Atara Biotherapeutics?

How do I contact Atara Biotherapeutics' investor relations team?

Atara Biotherapeutics' physical mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is 650-278-8930. The official website for Atara Biotherapeutics is www.atarabio.com.